"We are pioneering regenerative medicine therapies through biocompatible cells and tissue."

Britecyte   is a biotechnology company focused on the development of cell therapies to treat metabolic diseases and its complications. Our main focus is on a cell therapy for non-alcoholic steatohepatitis (NASH).

®

Metabolic disease impairs millions of lives resulting in low quality of life, high morbidity and mortality. Non-alcoholic steatohepatitis (NASH) is a serious liver disease triggered by disrupted metabolism.

Britecyte is developing a cell therapy that targets multiple pathways in NASH and in adipose tissue metabolism, the root cause of NASH. In addition to cell therapies, Britecyte is focusing on innovative regenerative medicine products for soft tissue defects repair, with a fast path to market.